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Letter to the Editor
Letter by Wang Regarding Article, 
“Renal Denervation for the Treatment of 
Cardiovascular High Risk-Hypertension  
or Beyond?”
To the Editor:
In their article titled “Renal denervation for the treatment of 
cardiovascular high risk-hypertension or beyond?” Böhm et al1 
presented an excellent overview on renal denervation and its 
clinical indications. The authors emphasized the blood pressure–
lowering effect of renal denervation. However, they did not cite a 
number of studies in which renal denervation did not lower office 
blood pressure2 or 24-hour ambulatory blood pressure.3–6 These 
uncited articles2–6 and the recently published Symplicity HTN-3 
trial7 clearly indicate that renal denervation does not lower blood 
pressure in every patient. The long-term safety of renal denerva-
tion has not been well established.8 Therefore, I agree with the 
authors’ opinion that renal denervation should only be performed 
in patients with resistant hypertension as ultima ratio, which was 
first suggested by Persu et al in 2012.9 However, Böhm et al1 also 
suggested further investigating whether pseudoresistant hyperten-
sion is also a target for renal denervation. This suggestion seems 
not appropriate, because (1) this suggestion is against the consen-
sus that renal denervation should be only used as ultima ratio and 
(2) a recent study has shown that pseudohypertension is not a risk 
factor if the patients are pharmaceutically treated.10 Therefore, ap-
plying renal denervation to patients with pseudoresistant hyper-
tension is not well justified.
Another point overlooked by the authors is that blood pressure 
in a large number of patients with resistant hypertension could be 
controlled by adjusting antihypertensive drugs. A recent study,11 in 
which 19 patients with resistant hypertension were randomized to 
adjusted drug treatment (n=10) and renal denervation (n=9), showed 
that adjusted drug treatment significantly decreased ambulatory 
blood pressure from 152/88 mm Hg at baseline to 133/77 mm Hg 
at 6 months. Renal denervation decreased ambulatory blood pres-
sure from 152/93 mm Hg at baseline to 142/86 mm Hg at 6 months, 
being inferior to adjusted drug treatment. In addition, ambulatory 
systolic blood pressure was decreased below 135 mm Hg in 7 of the 
10 patients by adjusting antihypertensive drugs.11 This study,11 for 
the first time, demonstrated that a large number of patients who are 
currently thought to have true resistant hypertension could be ef-
fectively treated by adjusting drugs. Therefore, adjusted drug treat-
ment is highly recommended before renal denervation.
In summary, renal denervation should be offered to patients 
with resistant hypertension as ultima ratio.9 Therefore, applying 
renal denervation to patients with pseudoresistant hypertension is 
not well justified, and adjusted drug treatment is highly recom-
mended before renal denervation.
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